Pharmacokinetic Clinical Trial
Official title:
A Non-randomized, Single-dose, Open-Label, Pharmacokinetic Study of Cebranopadol in Patients With Impaired Renal Function and Subjects With Normal Renal Function
The objective of this study was to evaluate the pharmacokinetics (PK), safety and tolerability profile of cebranopadol (GRT6005) in patients with varying degree of renal impairment and participants with normal renal function after an oral single dose administration. This study was a Phase 1, multi-center, non-randomized, open-label, parallel group, single-dose study in up to 24 male and female patients with varying degree of renal impairment and participants with normal renal function. Within 14 days before the administration of cebranopadol the general eligibility of the participants for the study was assessed according to the inclusion/exclusion criteria. Estimated glomerular filtration rate (eGFR) was determined according to the Modification of Diet in Renal Disease (MDRD) equation. A treatment period from Day -1 to Day 8 was performed, with participant confinement to the study site from Day -1 to Day 6 and an outpatient visit on Day 8. A single dose of cebranopadol 200 μg was administered on Day 1. Multiple blood and urine samples were drawn for pharmacokinetic evaluations and safety laboratory monitoring. Additional blood samples were taken prior investigational medicinal product (IMP) administration to assess serum creatinine concentration and protein binding. An End-of-Trial Visit was performed at the time, or within 7 days, of the final blood sample on Day 8 or at early withdrawal.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04531150 -
Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects
|
Phase 1 | |
Completed |
NCT03437265 -
A Pharmacokinetic Study of PLENVU® in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03979989 -
Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)
|
Phase 1 | |
Completed |
NCT00743912 -
Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05367011 -
Therapeutic Monitoring of Antibiotics in Intensive Care Patients: a Cohort Study PopTDM-ICU
|
||
Completed |
NCT06126562 -
A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects
|
Phase 1 | |
Completed |
NCT00745264 -
Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise
|
Phase 1 | |
Completed |
NCT03344627 -
Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients
|
N/A | |
Completed |
NCT01082796 -
Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects
|
N/A | |
Terminated |
NCT02696954 -
Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects
|
Phase 1/Phase 2 | |
Recruiting |
NCT03714568 -
Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.
|
Phase 1 | |
Recruiting |
NCT04080895 -
Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT04735913 -
Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults
|
Early Phase 1 | |
Completed |
NCT03011996 -
To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration
|
Phase 1 | |
Completed |
NCT00681395 -
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
|
Phase 1 | |
Completed |
NCT04617509 -
A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
|
Phase 1 | |
Terminated |
NCT03059511 -
Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants
|
Phase 1 | |
Withdrawn |
NCT05938608 -
A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body
|
Phase 1 | |
Completed |
NCT01091532 -
A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.
|
Phase 1 | |
Completed |
NCT03951402 -
Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women
|
Phase 1 |